GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Whites owned most of the best farmland, and had far superior education, wages and homes, but the schooling, healthcare, infrastructure and salaries available to black Rhodesians were nevertheless very good by African standards. In the wider Imperial context, Southern Rhodesia occupied a category unto itself because of the "special quasi-independent status" it held. The Dominions Office, formed in 1925 to handle British relations with the dominions of Australia, Canada, New Zealand, Newfoundland, South Africa and the Irish Free State (the Statute of Westminster 1931 delineated the rights of the dominions more clearly in that year), also dealt with Southern Rhodesia, and Imperial Conferences included the Southern Rhodesian Prime Minister alongside those of the dominions from 1932. This unique arrangement continued following the advent of Commonwealth Prime Ministers' Conferences in 1944. Southern Rhodesians of all races fought for Britain in the Second World War, and the colonial government gradually received more autonomy regarding external affairs. During the immediate post-war years, Southern Rhodesian politicians generally thought that they were as good as independent as they were, and that full autonomy in the form of dominionship would make little difference to them. Post-war immigration to Southern Rhodesia, mainly from Britain, Ireland and South Africa, caused the white community to swell from 68,954 in 1941 to 221,504 in 1961. The black population grew from 1,400,000 to 3,550,000 over the same period.
=== Similar species === Xanthoria parietina can be confused with several closely related species, particularly X. aureola and X. calcicola. Molecular evidence supports that these are distinct species, though they share morphological similarities. X. aureola was historically considered synonymous with X. parietina but is now recognized as a separate species. Compared to X. parietina, X. aureola has a thicker thallus (averaging 320 μm vs. 236 μm), narrower lobes at their widest point (averaging 2.3 mm vs. 2.9 mm), and a rough upper surface with visible crystals rather than smooth. The central parts of X. aureola are covered with overlapping, crenulate to strap-shaped lobules. It typically produces fewer apothecia, and shows an ecological preference for seashore rocks, while X. parietina occurs on various substrates. Xanthoria calcicola differs from X. parietina by its rough upper surface with crystals, central parts covered with coarse isidia or papilla-like projections, and dull orange-yellow color compared to the brighter yellow of X. parietina. It typically has scattered apothecia when present (versus abundant in X. parietina), thalline margins of apothecia that range from smooth to rough to crenulate, a distinct chemosyndrome (a set of related secondary metabolites), and preference for calcareous substrates like stone walls, rarely growing on bark. Molecular analysis shows X. calcicola and X. aureola are more closely related to each other than either is to X.
First Minister of Wales Eluned Morgan offers Plaid Cymru an open invitation to support the Welsh Government's budget, scheduled to be delivered by Finance Secretary Mark Drakeford on 10 December. Wales's health secretary, Jeremy Miles announces that private healthcare will be used to help reduce the patient backlog in the NHS, with £50m allocated for health to be given to Wales's health boards to provide more appointments, tests and treatments. 20 November – Peter Kyle, the Secretary of State for Science, Innovation and Technology, tells the BBC that a ban on social media for under-16s in the UK is "on the cards". 21 November – Stephen Flynn, the SNP's leader at Westminster, says he will not seek a dual mandate by standing for the Scottish Parliament while he remains an MP. 22 November – Downing Street indicates that Israeli prime minister Benjamin Netanyahu would face arrest if he travelled to the UK following the issuing of an international arrest warrant for war crimes by the International Criminal Court. Former prime minister Gordon Brown publicly declares his opposition to a new law on assisted dying. 23 November – The UK government advertises for a new negotiator which it hopes will deliver a "reset" of the UK's relationship with the European Union. Secretary of State for Justice Shabana Mahmood writes to her constituents saying she is "profoundly concerned" about the Terminally Ill Adults (End of Life) Bill, not only for religious reasons but because of what it would mean for the state if one of its roles became helping people to die.
Sources: en.wikipedia.org
ThO2 + 2 Ca → 2 CaO + Th Sometimes thorium is extracted by electrolysis of a fluoride in a mixture of sodium and potassium chloride at 700–800 °C in a graphite crucible. Highly pure thorium can be extracted from its iodide with the crystal bar process. Uranium is extracted from its ores in various ways. In one method, the ore is burned and then reacted with nitric acid to convert uranium into a dissolved state. Treating the solution with a solution of tributyl phosphate (TBP) in kerosene transforms uranium into an organic form UO2(NO3)2(TBP)2. The insoluble impurities are filtered and the uranium is extracted by reaction with hydroxides as (NH4)2U2O7 or with hydrogen peroxide as UO4·2H2O. When the uranium ore is rich in such minerals as dolomite, magnesite, etc., those minerals consume much acid. In this case, the carbonate method is used for uranium extraction. Its main component is an aqueous solution of sodium carbonate, which converts uranium into a complex [UO2(CO3)3]4−, which is stable in aqueous solutions at low concentrations of hydroxide ions. The advantages of the sodium carbonate method are that the chemicals have low corrosivity (compared to nitrates) and that most non-uranium metals precipitate from the solution. The disadvantage is that tetravalent uranium compounds precipitate as well. Therefore, the uranium ore is treated with sodium carbonate at elevated temperature and under oxygen pressure:
=== Later work === In 1965, Zuckerkandl moved back to France to direct in Montpellier, the "Centre de Recherche de Biochimie Macromoléculaire" of the Centre National de Recherche Scientifique. In 1971, he became the founding editor of the Journal of Molecular Evolution, and in the late 1970s became President of the Linus Pauling Institute (then in 1992 of its successor, the Institute of Molecular Medical Sciences). His recent work includes criticism of social constructionism and intelligent design.
=== Spring 1945 offensive in Italy === Kesselring's forces in Italy retained their formidable defensive positions in the northern Apennines in March 1945. The 6th Division rejoined the line in early April, shortly before the Allies launched their spring 1945 offensive, Operation Grapeshot. The units including Rhodesians took up positions opposite Monte Sole, Monte Abelle and Monte Caprara. The Rhodesian 25-pounder guns were posted slightly forward of their former positions, and B (Rhodesia) Squadron, Prince Alfred's Guard, moved to Grizzana. The Special Service Battalion provided armoured support to the 13th South African Motorised Brigade. The South Africans and Rhodesians launched a two-pronged assault on the German positions over the road to Bologna at 22:30 on 15 April 1945. The Cape Town Highlanders' advance up the steep cliffs of Monte Sole was obstructed by a German minefield that guarded the peak. The Rhodesian officer commanding the leading platoon, Second Lieutenant G B Mollett, took a section of men and dashed through the minefield to the summit; for this he later received the Distinguished Service Order. Hand-to-hand fighting on Monte Sole continued until dawn, when the Germans withdrew. The Witwatersrand Rifles meanwhile took Monte Caprara. The Cape Town Highlanders took Monte Abelle late on 16 April, advancing under heavy artillery fire to the summit before clearing it of Germans. The regiment lost 31 killed and 76 wounded during these actions, including three Rhodesians killed and three wounded.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.